ArticleBlood2024

Cost-effectiveness of prophylaxis with recombinant vs plasma-derived VWF in severe von Willebrand disease in the United States.

Christina Waldron et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.